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Pro-epileptogenic effects of viral-like
inflammation in both mature and immature
brains
Nina Dupuis1,2, Andrey Mazarati3, Béatrice Desnous1,2,4, Vibol Chhor1,2, Bobbi Fleiss1,2, Tifenn Le Charpentier1,2,
Sophie Lebon1,2, Zsolt Csaba1,2, Pierre Gressens1,2,4, Pascal Dournaud1,2† and Stéphane Auvin1,2,4*†
Abstract
Background: Infectious encephalitides are most often associated with acute seizures during the infection period
and are risk factors for the development of epilepsy at later times. Mechanisms of viral encephalitis-induced
epileptogenesis are poorly understood. Here, we evaluated the contribution of viral encephalitis-associated
inflammation to ictogenesis and epileptogenesis using a rapid kindling protocol in rats. In addition, we examined
whether minocycline can improve outcomes of viral-like brain inflammation.
Methods: To produce viral-like inflammation, polyinosinic-polycytidylic acid (PIC), a toll-like receptor 3 (TLR3)
agonist, was applied to microglial/macrophage cell cultures and to the hippocampus of postnatal day 13 (P13) and
postnatal day 74 (P74) rats. Cell cultures permit the examination of the inflammation induced by PIC, while the
in vivo setting better suits the analysis of cytokine production and the effects of inflammation on epileptogenesis.
Minocycline (50 mg/kg) was injected intraperitoneally for 3 consecutive days prior to the kindling procedure to
evaluate its effects on inflammation and epileptogenesis.
Results: PIC injection facilitated kindling epileptogenesis, which was evident as an increase in the number of full
limbic seizures at both ages. Furthermore, in P14 rats, we observed a faster seizure onset and prolonged retention
of the kindling state. PIC administration also led to an increase in interleukin 1β (IL-1β) levels in the hippocampus in
P14 and P75 rats. Treatment with minocycline reversed neither the pro-epileptogenic effects of PIC nor the increase
of IL-1β in the hippocampus in both P14 and P75 rats.
Conclusions: Hippocampal injection of PIC facilitates rapid kindling epileptogenesis at both P14 and P75,
suggesting that viral–induced inflammation increases epileptogenesis irrespective of brain maturation. Minocycline,
however, was unable to reverse the increase of epileptogenesis, which might be linked to its absence of effect on
hippocampal IL-1β levels at both ages.
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Background
Infectious encephalitides are most often associated with
seizures during the infection period [1, 2] and are estab-
lished risk factors for the development of epilepsy at later
times [1, 3, 4]. Although many infectious encephalitides
are of unknown origin, the majority of clinical studies
suggest a viral etiology [5, 6]. Common viruses associated
with encephalitis-induced seizures are herpes simplex and
cytomegalovirus. Children are three times more prone to
viral encephalitis than adults are [6, 7], moreover, infants
under 1 year are particularly affected [6]. Mechanisms
leading to increased seizure occurrence at the time of
infection and those underlying encephalitis-induced
epileptogenesis are poorly understood. Virus-induced cell
injury, brain inflammation, and initial prolonged seizures
appear to be key contributors to epileptogenesis after the
acute phase of encephalitis [2, 8–10].
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There are several models of virus-induced encephalitis.
However, most experimental animals die during the
acute infection period, rendering the study of epilepto-
genesis impossible [11]. The use of the Daniel’s (DA)
strain of Theiler’s murine encephalomyelitis virus
(TMEV) in C57Bl6 mice leads to behavioral seizures
during the acute phase in 75% of the animals [10]. A
significant proportion (65%) of the animals with acute
symptomatic seizures develops spontaneous recurrent
seizures later in life [10]. In this model, macrophages
have been shown to be associated with seizures during
the acute phase of encephalitis, while neuronal loss and
inflammation contribute to epileptogenesis [8, 12].
In the central nervous system (CNS), the innate
inflammatory response to viral infection primarily
involves the activation of microglia, which are cerebral
monocyte-like immune cells [13]. The innate inflamma-
tory response is triggered by pattern-recognition recep-
tors, including toll-like receptors (TLRs), RIG1-like
receptors, and nucleotide-binding oligomerization
domain-like receptors [14]. TLR3 is a receptor for
double-stranded RNA, which is released by viruses and
necrotic cells. Upon activation, TLR3 triggers cytokine
and interferon production pathways [15, 16].
Clinical and experimental data suggest an important
role for neuroinflammation in seizure occurrence and
epileptogenesis [17]. A direct role of cytokines, and
particularly of interleukin 1β (IL-1β), has been demon-
strated in the precipitation of seizures during brain in-
flammation. Cytokines have also been implicated in
epileptogenesis. Therapeutic targeting of IL-1β has been
proven effective in inhibiting epileptogenesis [18, 19].
Since encephalitis in humans is more frequent in chil-
dren than in adults, we decided to evaluate the contribu-
tion of brain viral-like inflammation to epileptogenesis
in not only mature but also in immature brains. To
induce brain viral-like inflammation, we injected a TLR3
agonist, polyinosinic-polycytidylic acid (PIC) [20], into
the hippocampus, which produces an inflammatory
response in the absence of viral replication. Unlike the
TMEV model, this model allows us to explore the role
of brain inflammation in the absence of viral replication-
induced brain injury. Moreover, our kindling model,
which is a model of compressed epileptogenesis, allows
us to perform the experiment during a precise window
of brain maturation.
We first characterized the response to PIC both in
vitro and in vivo. Since macrophages contribute to
epileptogenesis in the TMEV model, we decided to study
microglial cells and macrophages to evaluate potential
differences that might derive from specific contributions
of these cell types. The second part of the study
consisted of the assessment of the effects of intrahippo-
campal PIC injection on hippocampal excitability and
epileptogenesis using the rapid kindling model. We
conducted the study in P14 and P75 animals to evaluate
whether brain maturation contributes to a higher sus-
ceptibility to inflammatory responses and epileptogen-
esis. Finally, we evaluated the effects of minocycline, an
antibiotic described as a modulator of inflammation
[21–23], on the inflammatory response to and the
modulation of seizures induced by PIC.
Methods
Animals
Male Wistar rats (Charles River, L’Arbesle, France) were
used for the rapid kindling and cytokine-dosage experi-
ments. We used P13 and P74 rats at the time of the PIC
intrahippocampal injection. Primary microglial and
macrophage cell cultures were prepared from the neo-
cortex of OF1 mice (Charles River, L’Arbesle) and 2-
month-old OF1 male mice (Charles River). Animals
were housed in standard laboratory conditions with con-
trolled temperature/humidity, a 12:12-hour light/dark
cycle, and free access to food and water. Studies were
approved by the animal ethical institutional review com-
mittee (Bichat-Robert Debré ethical committee, Paris,
France, #2015072801547679) and met stipulations of the
guide for the care and use of laboratory animals (NIH,
Bethesda, Maryland, USA), as well as recommendations
of reduction, refinement, and replacement (known as
the 3 Rs) [24].
Drugs
PIC and minocycline (Sigma, Lyon, France) were
dissolved in saline for the in vivo experiments and in
phosphate buffered saline (PBS) for the in vitro experi-
ments. PIC (10 μg/rat) was injected stereotaxically into
the ventral hippocampus 24 h before rapid kindling at
the following coordinates: P13, 3.0 mm posterior,
3.9 mm left, 4.2 mm ventral; P74, 4.8 mm posterior,
5.3 mm left, 6.5 mm ventral, in relation to bregma. The
injection of PIC into the hippocampus aims to mimic
encephalitis, which is characterized by brain inflamma-
tion, rather than meningitis, which is inflammation in
the meninges and the cerebrospinal fluid (CSF). Minocy-
cline (50 mg/kg) was administered as 3 consecutive
intraperitoneal (i.p.) injections 48, 24, and 4 h before the
start of the kindling protocol. Table 1 summarizes the
in vitro and in vivo experiments.
Microglia primary cell cultures
Primary mixed glial cell cultures were prepared from the
neocortices of P0-P1 OF1 mice, as described previously
[25, 26]. Briefly, the cortices were dissected and the
meninges were removed in 0.1 M PBS with 6% glucose
and 2% penicillin–streptomycin (PS, Gibco, Cergy Pon-
toise, France). The tissue was subsequently mechanically
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dissociated and spun at 1000 rpm for 5 min at 4 °C. The
pellet was resuspended in low-glucose Dulbecco’s modi-
fied Eagle’s minimum essential medium (DMEM, 31885,
Gibco) supplemented with 10% fetal bovine serum (FBS,
Gibco) and 0.01% PS. The cells were then plated in
poly-D-L-ornithine-coated T75 flasks. Microglia were
isolated from the primary mixed glial cultures on day
in vitro 14 by shaking for 20 min. The supernatant was
collated and spun at 1800 rpm for 5 min at 4 °C. Micro-
glia were resuspended in DMEM supplemented with
0% FBS in 6-well culture plates and cultured for 1 day
before treatment.
Microglia were exposed for 4 h to PBS or PIC (1 μg/
ml). Supernatants were collected and stored at −80 °C
until cytokine levels were measured. Cells were har-
vested and RNA was extracted for gene expression
analysis.
Peritoneal macrophage primary cell cultures
Primary peritoneal macrophage cultures were prepared
from 2-month-old OF1 male mice, as described previ-
ously [27]. Macrophages were isolated by peritoneal lav-
age with ice-cold PBS. After 400 × g centrifugation, cells
were resuspended in DMEM/F12 medium (Gibco, Cergy
Pontoise, France) supplemented with 10% FBS (Gibco)
and 0.01% PS (Gibco) in 6-well culture plates. After 1 h,
non-adherent cells were removed by washing and adher-
ent cells were found to be ~95% pure based on
morphological criteria. Cells were cultured for 1 day be-
fore treatment.
Similar to microglia, macrophages were exposed to
PBS or PIC (4-hour; 1 μg/ml). Supernatants were col-
lected and stored at −80 °C until cytokine level measure-
ments. Cells were harvested and RNA was extracted for
gene expression analysis.
RNA extraction and quantitative PCR
Total RNA from primary microglial cell cultures was ex-
tracted using the RNeasy mini kit according to the man-
ufacturer’s instructions (Qiagen, Courtaboeuf, France).
Total RNA (500 ng) was subjected to reverse transcrip-
tion based on equal amounts of RNA using the iScript™
cDNA synthesis kit (Bio-Rad, Marnes-la-Coquette,
France). Quantitative PCR was then performed in dupli-
cate for each sample using the SYBR Green Supermix
(Bio-Rad) for 40 cycles with a two-step program (5 s of
denaturation at 96 °C, and 10 s of annealing at 60 °C).
The primers used are summarized in Table 2. The rela-
tive expression of genes of interest was compared with
that of the reference gene, glyceraldehyde-3-phosphate
dehydrogenase (Gapdh). Analyses were performed using
Biorad CFX Manager 3.0 software.
Multiplex cytokine assay
Freshly excised hippocampi from P14 and P75 rats (24 h
after ventral hippocampal injection) were homogenized
and total protein was extracted in PBS supplemented
with protease inhibitors (Roche Diagnostics, Meylan,
France). After a 12500-rpm centrifugation for 30 min,
supernatants were collected.
IL-1β, interleukin 6 (IL-6), tumor necrosis factor α
(TNFα), and interleukin 10 (IL-10) levels were measured
in microglia supernatants and hippocampal protein
Table 1 Experimental plan summarizing treatments and
experiment (exp.) numbers included in the study
Cell culture experiments In vivo experiments
Microglia Rapid kindling protocol
RT-PCR: PBS vs. PIC, n = 5 (x3 exp.) P14: saline (n = 5) vs. PIC (n = 6)
Luminex: PBS vs. PIC, n = 5
(x1 exp.)
P75: saline (n = 6) vs. PIC (n = 7)
RT-PCR: PIC vs. PIC + Mino, n = 5
(x3 exp.)
P14: mino (n = 7) vs. PIC +
Mino (n = 7)
Luminex: PIC vs. PIC + Mino,
n = (x1 exp.)
P75: mino (n = 5) vs. PIC +
Mino (n = 5)
Macrophages Cytokines dosage by luminex
RT-PCR: PBS vs. PIC, n = 5 (x3 exp.) P14: saline i.p. + saline i.h. (n= 5)
Luminex: PBS vs. PIC, n = 5
(x1 exp.)
Saline i.p. + PIC i.h. (n = 5)
RT-PCR: PIC vs. PIC +mino, n = 5
(x3 exp.)
Mino i.p. + saline i.h. (n = 5)
Luminex: PIC vs. PIC + mino, n = 5
(x1 exp.)
Mino i.p. + PIC i.h. (n = 5)
P75: Saline i.p. + saline i.h. (n= 5)
Saline i.p. + PIC i.h. (n = 5)
Mino i.p. + saline i.h. (n = 5)
Mino i.p. + PIC i.h. (n = 5)
Table 2 List of PCR primers used in the study
Gene Forward primer (5′−3′) Reverse primer (5′−3′)
Gapdh GGC CTT CCG TGT TCC TAC TGT CAT CAT ACT TGG CAG GTT
Il1β GGG CCT CAA AGG AAA GAA TC TCT TCT TTG GGT ATT GCT TGG
Il6 CAA AGC CAG AGT CCT TCA GA GCC ACT CCT TCT GTG ACT CC
Tnfα GCC TCT TCT CAT TCC TGC TT AGG GTC TGG GCC ATA GAA CT
Il1rn TTG TGC CAA GTC TGG AGA TG TTC TCA GAG CGG ATG AAG GT
NfκB TTA CAT TCC ATC CCG GAG TC GCA CAA TCT TTA GGG CCA TT
IκB CTC ACG GAG GAC GGA GAC T GTC TCC CTT CAC CTG ACC AA
Ifnβ TGA ACT CCA CCA GCA GAC AG GGA CAT CTC CCA CGT CAA TC
Trif GCT CCA GGC TTC ATT CTC C AAG GCA CCT AGA ATG CCA AA
Tbk1 ATA AGC TTC CTT CGC CCA GT CCA CAG GGA CAA AAC TCC AT
Irf3 GAT GGC TGA CTT TGG CAT CT GAC ACG TCC GGC TTA TCC T
Ptgs2 TCA TTC ACC AGA CAG ATT GCT AAG CGT TTG CGG TAC TCA TT
Nos2 CCC TTC AAT GGT TGG TAC ATG G ACA TTG ATC TCC GTG ACA GCC
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extracts using a Bio-plex 200 and a 96-well magnetic
plate assay according to the manufacturer’s instructions
(Biorad Laboratories, Marnes la Coquette, France). All
samples were run in duplicate, and data were analyzed
using Bio-Plex Manager software. For hippocampal mea-
surements, cytokine levels were expressed relative to
total protein levels (pg of cytokine/mg of total protein).
Immunohistochemistry
Twenty-four hours after the hippocampal PIC injection,
P14 and P75 rats (n = 5 for each experimental group)
underwent transcardiac perfusion with 4% paraformalde-
hyde. Coronal 30-μm-thick free-floating sections were
immunolabeled overnight with rabbit polyclonal anti-
ionized calcium binding adaptor molecule 1 (Iba1)
(1:1000, Wako) and mouse monoclonal anti-glial fibril-
lary acidic protein (GFAP) (1:500, Sigma) antibodies and
revealed by Alexa Fluor 488- and Cy3-conjugated anti-
rabbit and anti-mouse secondary antibodies (1:500,
Invitrogen).
Sections of the ventral hippocampus at the PIC or sa-
line injection sites were imaged using a fluorescence
microscope (Zeiss Axio Observer Z1). Immunopositive
cells were quantified by a cell count in six different areas
distant from the injection site in each animal (square;
Fig. 3) using ImageJ software.
Rapid kindling protocol
Animals were anesthetized with isoflurane, stereotaxic-
ally injected with 10 μg of PIC (1 μl in the left hippo-
campus), and implanted with a bipolar stimulating
electrode (Plastics One Inc., Roanoke, VA) into the left
ventral hippocampus. The coordinates in relation to
bregma were as follows: P13, 3.0 mm posterior, 3.9 mm
left, 4.2 mm ventral; P74, 4.8 mm posterior, 5.3 mm left,
6.5 mm ventral. A tripolar recording electrode was
wrapped around the skull screws above the right hemi-
sphere. Electrodes were fixed to the skull using Integrity
composite resin (Densply, York, PA, U.S.A.).
Twenty-four hours after surgery, the animals were
connected to a DS8000 electrical stimulator via DLS100
stimulus isolators (World Precision Instruments, Sara-
sota, FL, U.S.A.). Electroencephalograms (EEGs) were
acquired using the MP100/EEG100B acquisition system
and AcqKnowledge software (BIOPAC, Santa Barbara,
CA, U.S.A.). The electrical stimulus used for the assess-
ment of the ictogenesis parameters and the kindling
protocol was a square wave biphasic electrical stimulus
with the following characteristics: 10-second train dur-
ation, 20 Hz, 1-ms pulse duration, delivered every 5 min.
At 24 and 48 h post-injection, afterdischarge threshold
(ADT) and afterdischarge duration (ADD) were assessed
using 0.1 mA incremental currents delivered every
5 min. An AD was defined as paroxysmal epileptiform
activity lasting at least 5 s with peak-to-peak amplitude
of at least twice the baseline background EEG observed
after the end of the hippocampal electrical stimulation.
The kindling protocol consisted of 60 trains delivered
every 5 min with a current of 0.1 mA over the ADT with
parameters otherwise similar to those described for
afterdischarge detection. Animals were video-recorded
during the kindling procedure. Behavioral seizures were
scored using Racine’s scale: 1, motor arrest and twitching
vibrissae; 2, chewing, head bobbing; 3, forelimb clonus;
4, forelimb clonus and rearing; 5, rearing and falling.
Epileptogenesis was analyzed by calculating the numbers
of kindling trials needed to first reach a stage 4–5 seiz-
ure and the total numbers of stage 4–5 seizures during
the kindling procedure. Ictogenesis was analyzed by cal-
culating changes in afterdischarge properties 24 h after
the kindling procedure compared to baseline after-
discharge properties. We also determined the severities
of behavioral seizures in response to the threshold
stimulation in the kindled animals [28–30].
Statistical analysis
Data were analyzed using Prism 5 software (Graphpad,
San Diego, CA, U.S.A.). Data were expressed as mean ±
standard errors of the mean. Statistical analyses were
performed using Kruskal-Wallis followed by Dunn’s
posthoc tests and the Mann-Whitney test to compare
two groups.
Results
PIC triggers inflammatory responses in both microglia
and macrophages
We produced primary cell cultures of both microglia
and macrophages to study inflammatory responses to
PIC. In microglial cells, PIC treatment increased mRNA
levels of Il-1β, Il-6, Tnfα, interferon β (Infβ), and inter-
leukin 1 receptor antagonist (IL-1rn), as well as of acti-
vators of TLR3 transduction pathways (i.e., nuclear
factor kappa-light-chain-enhancer of activated B cells
(NfκB), nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor, alpha (IκB), TIR-domain-
containing adapter-inducing interferon-β (Trif ), and
TANK-binding kinase (Tbk1)). Ptgs2 and Nos2 (coding
for cyclooxygenase2 and inducible nitric oxide synthase
proteins, respectively) mRNA levels were also increased
after PIC exposure (Fig. 1a). The levels of pro-
inflammatory cytokines were consistent with the reverse
transcriptase-PCR findings and indicated increases in
the levels of IL-1β, IL-6, and TNFα after PIC exposure
(Fig. 1c). In macrophages, we observed a similar profile
of inflammatory activation by studying mRNA expres-
sion after PIC exposure (Fig. 1b). We found increases of
IL-6 and TNFα not of IL-1β in the supernatant after PIC
exposure (Fig. 1c).
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Fig. 1 (See legend on next page.)
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Hippocampal injection of PIC triggers an inflammatory
IL-1β response
Following the injection of PIC into the hippocampus, we
observed an increase in IL-1β compared to the controls
at both ages (Fig. 2). In contrast, IL-6, TNFα and IL-10
protein levels were unchanged 24 h after PIC injection
at both ages (Fig. 2). The intracerebral PIC injection did
not result in any change in the blood cytokine levels
(Additional file 1).
Hippocampal injection of PIC does not change the
numbers of glial cells in vivo
In order to determine whether IL-1β production is asso-
ciated with glial activation, we analyzed microglia and
astrocyte distribution in the hippocampus. Twenty-four
hours after the intrahippocampal injection of PIC, the
density of Iba1-expressing cells was not different from
those found in controls in either age group (Fig. 3).
Similarly, in both age groups, the density of GFAP-
expressing cells was not different from that of the
controls (Fig. 3). Around the injection site, where we
observed glial activation (Fig. 3), no difference in the rela-
tive intensities of both Iba1- and GFAP immunoreactive
signals was observed in PIC-injected vs. saline control
animals (Fig. 3c).
Hippocampal injection of PIC facilitates epileptogenesis in
both P14 and P75 rats
We used a rapid kindling model to determine whether
intrahippocampal injection of PIC produces pro-
ictogenic and/or pro-epileptogenic effects. First, AD pa-
rameters were not changed by PIC administration. This
suggests that there were no changes in ambient hippo-
campal excitability at either P14 or P75 (Fig. 4a, b).
Second, kindling epileptogenesis was facilitated by
PIC; this was evident as an increase in the numbers of
full limbic (i.e., stage 4–5) seizures (P14: 23.3 ± 2.4 vs.
10.2 ± 2.6, p < 0.01; P75: 15.6 ± 1.1 vs. 8.8 ± 1.3, p < 0.01;
comparisons are for PIC vs. saline) and a faster onset of
stage 4–5 seizures in P14 animals (number of trials to
first stage 4–5 seizure: P14, 11.2 ± 3.5 vs. 27.8 ± 5.0, p <
0.05; comparison is for PIC vs. saline) (Fig. 5a, b).
Third, the modification of AD properties after kindling
by PIC was more evident in P14 rats. 24 h after the
kindling procedure, PIC further increased the scores of
seizures induced by threshold stimulation in P14 rats
(Fig. 5a). There was no difference in AD threshold
(See figure on previous page.)
Fig. 1 Inflammatory response to PIC treatment in microglial and macrophage primary cell cultures. mRNA quantification by RT-qPCR of inflammatory
actors in microglial (a) and macrophage (b) primary cultures 4 h after PBS or PIC exposure (1 μg/ml). Cytokine profile (IL1β, IL6, TNFα) 4 h after PBS or
PIC exposure (1 μg/ml) in primary microglial and macrophage cell culture supernatants (c). Data are presented as mean ± SEM. *p < 0.05, **p < 0.01 vs.
PBS (Mann-Whitney test)
Fig. 2 Hippocampal cytokine levels 24 h after PIC injection. Cytokine profiles (IL1β, IL6, IL10, TNFα) in the hippocampus 24 h after
intrahippocampal injection (saline i.p. + saline i.h., saline i.p. + PIC i.h. (10 μg/rat), minocycline i.p. (50 mg/kg) + saline i.h. or minocycline i.p.
(50 mg/kg) + PIC i.h. (10 μg/rat)) in P14 and in P75 rats. Data are presented as mean ± SEM. *p < 0.05 vs. all other treatment groups according to
age group (Kruskal-Wallis test)
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Fig. 3 (See legend on next page.)
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between the PIC and control groups at P14 (Fig. 5a).
None of these parameters (AD parameters and seizure
scores at retest) were changed in P75 rats (Fig. 5b).
Inefficiency of minocycline in the PIC-facilitated epilepto-
genesis in both P14 and P75 rats
To test possible modulations of the pro-epileptogenic ef-
fects of PIC by minocycline, we administered minocy-
cline (50 mg/kg i.p.) over three consecutive days to
animals at both ages, with and without intrahippocampal
PIC injections (Figs. 4 and 5). First, in AD parameters,
we detected a decrease of ADT in minocycline-treated
P14 animals as compared to saline controls (Fig. 4a).
Second, kindling epileptogenesis facilitated by PIC was
not inhibited by minocycline (Fig. 5). Third, after kind-
ling completion, minocycline did not reduce the pro-
epileptogenic effects of PIC (Fig. 5). On the contrary, the
ADT in minocycline-treated P14 animals was still de-
creased as compared to saline controls (Fig. 5a).
Minocycline does not modulate IL-1β level in the
hippocampus
Hippocampal level of IL-1β increased by PIC was not
modified by minocycline treatment at both ages. TNFα
was however reduced in the PIC-injected group by min-
ocycline in P14 rats as compared to controls (Fig. 2).
Discussion
In this study, we demonstrated that PIC induced an in-
flammatory response in both microglial cells and macro-
phages in vitro. It also led to a pro-inflammatory
response in the hippocampi of both P14 and P75 rats
but was limited to an increase of IL-1β. Furthermore,
PIC accelerated epileptogenesis at both ages without
changing baseline hippocampal excitability. Using mino-
cycline as an anti-inflammatory agent, we were not able
to reverse the pro-epileptogenic effects of PIC. This
might be attributed to its inability to change the IL-1β
hippocampal levels in our experimental settings.
PIC mimics viral infection via binding to TLR3 [15,
16, 20] and results in an inflammatory response [31].
However, there are limited data regarding the exact role
of microglial cells in the viral-like inflammatory response
induced by PIC [20]. In our primary microglial cultures,
PIC resulted in the activation of TLR3 downstream
pathways (i.e., increased mRNA expression levels of Trif,
NfκB/IκB, and Tbk1) and in the release of IL-1β, IL-6,
and TNFα proteins. This is consistent with previous
work using higher doses of PIC (50 μg/ml) [20]. We
found a similar inflammatory response in both microglia
and macrophages, the only difference being that IL-1β
was significantly increased by PIC only in microglial cell
cultures. This might be a characteristic of our model, as
IL-6 release by both infiltrating macrophages and resi-
dent microglia has been observed in previous virus-
induced encephalitis models, and has been shown to
contribute to the precipitation of seizures [8, 9, 32].
The injection of PIC into the hippocampus indeed re-
sulted in an increase in IL-1β levels in both age groups.
This was not associated with any extensive cell injury or
changes in microglial or astrocytic densities within the
hippocampus. In addition, we did not find any difference
in blood cytokine levels after PIC injection which ex-
cludes the contribution of peripheral inflammation in
(See figure on previous page.)
Fig. 3 Glial activation at the injection site 24 h after PIC or saline injection. Low (a) and high (b) magnifications of representative pictures of
microglial cells (Iba1, red) and astrocytes (GFAP, green) in the hippocampus 24 h after intrahippocampal injection (saline vs. PIC 10 μg/rat) in P14
and P75 rats. The white rectangle represents an area of cell count. Quantifications of microglial cell (Iba1) and astrocyte (GFAP) number (c). Data
are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs. saline (Mann-Whitney test). Scale bars: a 200 μm; b 50 μm
Fig. 4 Effect of PIC and minocycline treatments on hippocampal excitability in P14 and P75 rats. Afterdischarge threshold (ADT) and
afterdischarge duration (ADD) 24 h after intrahippocampal injection (saline vs. PIC 10 μg/rat) and the last minocycline intraperitoneal injection
(Saline +minocycline vs. PIC 10 μg/rat + minocycline) in P14 (a) and in P75 rats (b). Data are presented as mean ± SEM. **p < 0.01 vs. saline
(Mann-Whitney test)
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our model. Together with our in vitro results, one
might hypothesize, that even in the absence of cell pro-
liferation, microglial activity is increased by PIC and
could be the main source of IL-1β. However, our
current data can not exclude the presence of macro-
phages in the brain tissue. Our results in P14 rats are in
line with those of a previous study showing increases in
IL-1β in P14 rats after intracerebroventricular (i.c.v.)
injection of PIC [33]. TNFα levels were also not chan-
ged in this latter study. Further studies are mandatory
to determine the exact contribution of the different in-
flammatory cell types to the production of cytokines in
the viral-like inflammation induced by PIC. Moreover,
we can not exclude that glial cell activation might occur
at later time points.
Intrahippocampal injection of PIC did not change
baseline hippocampal excitability in P14 and P75 rats
despite leading to increase in IL-1β levels. IL-1β has
been consistently described as a factor promoting
seizures in both the mature and the immature brain.
In adult rats, intrahippocampal injection of IL-1β in-
creases the durations of kainate-induced seizures
[34]. In the developing brain, i.c.v. injection of IL-1β
leads to pro-convulsant effects in various seizure
models [35, 36]. In these former studies, however,
IL-1β was directly injected within the brain. By con-
trast in our model, IL-1β is intrinsically produced
thus suggesting that the concentration reached is not
sufficient to facilitate ictogenesis.
Interestingly, intrahippocampal injection of PIC facili-
tated epileptogenesis at both ages. Our results are
consistent with the implication that IL-1β has a role in
epileptogenesis [37]. This was first suggested by the
upregulation of IL-1β in the hippocampi of chronically
epileptic mice and in resected hippocampal tissue from
patients with temporal lobe epilepsy [38, 39]. The
importance of IL-1β in epileptogenesis was further
supported by the finding that VX-765, a selective inhibitor
of caspase 1, counteracted kindling in adult rats when ad-
ministered concomitantly with a blockade of IL-1β in-
crease in astrocytes [19]. In agreement with our results,
the i.c.v. injection of PIC in P14 rats resulted in an imme-
diate increase in the hippocampal levels of IL-1β without
causing any changes in TNFα levels, and was followed by
a long-term modification of seizure susceptibility [33], fur-
ther supporting that IL-1β is a key factor in the facilitation
of epileptogenesis by viral-like inflammation.
Minocycline, a semi-synthetic tetracycline antibiotic
[40], exerts a variety of biological effects, including pro-
teolysis inhibition, antioxidant effects, and anti-apoptotic
and anti-inflammatory activities [23, 41–44]. Minocy-
cline is also well-known to inhibit microglial activation
[21, 22, 45]. We first hypothesized that minocycline
might modulate the PIC-induced increase in the epilep-
togenesis through the modulation of inflammation. This
assumption was based on previous reports, which have
shown that minocycline is able to counteract the long-
term increase in brain excitability produced in neonatal
Fig. 5 Effects of PIC and minocycline treatments on epileptogenesis. Kindling progression parameters 24 h after intrahippocampal injection
(saline vs. PIC 10 μg/rat) and the last minocycline intraperitoneal injection (Saline + minocycline vs. PIC 10 μg/rat + minocycline) and
afterdischarge (AD) properties at retest, 24 h after kindling onset in P14 (a) and in P75 rats (b). Total number of stages 4-5 seizures and number of
stimulations to achieve stage 4–5 seizure in P14 (a) and P75 rats (b). Afterdischarge threshold (ADT), afterdischarge duration (ADD), and seizure
score at retest in P14 (a) and P75 rats (b) 24 h after kindling onset. Data are presented as mean ± SEM. *p < 0.05 vs. saline (Mann-Whitney test)
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rats subjected to an i.c.v. injection of PIC [33]. By
decreasing microglial cell activation/proliferation under
conditions of status epilepticus induced in juvenile mice
by kainate, minocycline limits the kainate-mediated low-
ering of the seizure threshold [46]. Moreover, the anti-
convulsant effects of minocycline have been reported in
the amygdala-kindling and the 6-Hz models of adult ani-
mals [47, 48]. However, in our model, we did not
observe any effect of minocycline on the rapid kindling
epileptogenesis and on the pro-epileptic effect of PIC
both in P14 and P75 rats. This might be, in part, due to
the inability of minocycline to inhibit intrinsic PIC-
mediated IL-1β production. Paradoxically, we found a
decrease in ADT before and after kindling in P14 rats.
This pro-ictogenic effect of minocycline might be associ-
ated with some of the paradoxical effects of minocycline
described in the developing brain [49] and remains to be
studied in details.
Conclusion
The PIC model allowed us to evaluate the involvement of
TLR3 agonists in epileptogenesis. Intrahippocampal injec-
tion of PIC induced brain inflammation and in particular
increased IL-1β levels as well as facilitated kindling epilep-
togenesis. PIC produced similar effects in P14 and P75
rats, suggesting that mature and immature brains share
common mechanisms in our model. Further research is
clearly needed to evaluate the key factors involved in the
facilitation of epileptogenesis by viral encephalitis, and
more specifically to establish the role of IL-1β.
Additional file
Additional file 1: Blood cytokine levels 24 h after PIC injection
measured by Multiplex cytokine assay. Cytokines profile (IL1β, IL6, IL10,
TNFα) in the blood 24 h after intrahippocampal injection (saline i.h (white
bar) or PIC i.h. (10 μg/rat) (black bar) in P14 and in P75 rats. Data are
presented as mean ± SEM. We did not find any difference between the
groups. (DOCX 9451 kb)
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